



Veltuzumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name

Veltuzumab

Accession Number

DB05656

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies

Monoclonal antibody (mAb)

Description

Veltuzumab is a monoclonal antibody which is being investigated for the treatment of non-Hodgkin's lymphoma. As of October 2009, it is undergoing Phase I/II clinical trials.

Protein structure



Protein chemical formula

C₆₄₅₈H₉₉₁₈N₁₇₀₆O₂₀₂₆S₄₆

Protein average weight

Not Available

Sequences

```
>8932_H|veltuzumab|Humanized||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-234)+CH2(235-344)+CH3(345-451))|||||451||||MW 49467.6|MW 49467.6|
```

```
QVQLQQSGAEVKKPGSSVKVSKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGNGDTSY
NQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTITVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
```

```
>8932_L|veltuzumab|Humanized||L-KAPPA (V-KAPPA(1-106)+C-KAPPA(107-213))|||||213||||MW
23205.8|MW 23205.8|
```

```
DIQLTQSPSSLSASVGRVTMTCRASSSVSYIHWFQQKPGKAPKPKWIYATSNLASGVPVR
FSGSGSGTDYFTFISLQPEDIATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
```


[Download FASTA Format](#)

Synonyms

Not Available

External IDs

hA20 / IMMU-106



[Antibodies, Monoclonal](#)

[Blood Proteins](#)

[Globulins](#)

[Immunoglobulins](#)

[Immunoproteins](#)

[Proteins](#)

[Serum Globulins](#)

UNII

[BPD4DGQ314](#)

CAS number

728917-18-8

PHARMACOLOGY

Indication

Investigated for use/treatment in lymphoma (non-hodgkin's).

Pharmacodynamics

Not Available

Mechanism of action


Not Available

Absorption

Not Available

Volume of distribution

Not Available



Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs [i](#)

Not Available

INTERACTIONS

Drug Interactions [i](#)

ALL DRUGS

APPROVED

VET APPROVED

NUTRACEUTICAL

ILLICIT



WITHDRAWN

INVESTIGATIONAL

EXPERIMENTAL



Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Veltuzumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Veltuzumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Veltuzumab.
Anthrax immune globulin human	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Veltuzumab.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Veltuzumab.
Bacillus calmette-guerin substrain connaught live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Veltuzumab.
Bacillus calmette-guerin substrain tice live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Veltuzumab.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Veltuzumab.
BCG vaccine	The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Veltuzumab.
Belimumab	The risk or severity of adverse effects can be increased when Veltuzumab is combined with Belimumab.

Showing 1 to 10 of 48 entries

< >

Food Interactions

Not Available

REFERENCES

General References

Not Available



CLINICAL TRIALS

Clinical Trials

Search

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
1, 2	Active Not Recruiting	Treatment	Aggressive NHL / Lymphoma, Large B-Cell, Diffuse (DLBCL) / NHL / Non Hodgkin Lymphoma (NHL)	1
1, 2	Active Not Recruiting	Treatment	Autoimmune Thrombocytopenic Purpura / Purpura, Thrombocytopenic, Autoimmune / Purpura, Thrombocytopenic, Idiopathic	1
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Leukemia, B-Cell, Chronic / Leukemia, Prolymphocytic / Leukemia, Small Lymphocytic / Lymphoma, B-Cell / Lymphoma, Intermediate-Grade / Lymphoma, Large-Cell / Lymphoma, Low-Grade / Lymphoma, Lymphoplasmacytoid, CLL / Lymphoma, Mixed-Cell / Lymphoma, Small-Cell / Lymphoplasmacytoid Lymphoma, CLL / NHL / Non-Hodgkin's Lymphoma (NHL) / SLL / Small Lymphocytic Lymphoma (SLL)	1
1, 2	Completed	Treatment	Lymphoma, Diffuse / Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic / Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Completed	Treatment	Malignant Lymphomas	1
1, 2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Terminated	Treatment	Follicular Lymphoma (FL)	1
2	Terminated	Treatment	Rheumatoid Arthritis	1

Showing 1 to 8 of 8 entries

< >



Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

PROPERTIES

State

Solid

Experimental Properties

Not Available

TAXONOMY


Description

Not Available

Kingdom

Organic Compounds

Super Class



Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent

Peptides

Alternative Parents

Not Available

Substituents

Not Available

Molecular Framework

Not Available

External Descriptors

Not Available

Drug created on November 18, 2007 11:26 / Updated on August 02, 2018 05:32

About

[About DrugBank](#)

[DrugBank Blog](#)

[Wishart Research Group](#)

[Terms of Use](#)

[Privacy Policy](#)

Support

[FAQ](#)

[Help](#)

[API Docs](#)[Data Licenses](#)[Support](#)

This project is supported by the **Canadian Institutes of Health Research** (award #111062), **Alberta Innovates - Health Solutions**, and by **The Metabolomics Innovation Centre (TMIC)**, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe Design & Innovation Inc.**

